Orgenesis secures $50m from Metalmark to develop CGTs at point of care 10-Nov-2022 By Jane Byrne Orgenesis, the biotech specializing in cell and gene therapy (CGT) at the point of care, and private equity firm, Metalmark, have signed a major investment partnership.